6 completed, 4 terminated, 2 unknown, 1 active not recruiting. 14 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 6, Terminated 4, Unknown 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Pemphigus: new trials by email Literature Review of Pemphigus trials Research Report on Pemphigus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of B007 in the Treatment of Pemphigus. B007 - Pemphigus | Phase 2 / Phase 3 | Recruiting | Shanghai Jiaolian Drug Research and Development Co., Ltd | 132 | 2024-07-12 | 2026-05-05 |
| Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid Ozonated olive oil, Topical garamycin cream - Pemphigus Vulgaris, Bullous Pemphigoid | Phase 3 | Unknown | Cairo University | 30 | 2022-11-01 | 2022-11-08 |
| ONO-4059 Study in Patients With Steroid-resistant Pemphigus ONO-4059, ONO-4059 placebo - Pemphigus, Steroid-resistant Pemphigus | Phase 3 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 34 | 2022-08-15 | 2026-07-20 |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) efgartigimod PH20 SC, prednisone - Pemphigus Vulgaris, Pemphigus Foliaceus | Phase 3 | Terminated | argenx | 183 | 2021-07-15 | 2025-03-30 |
| A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) efgartigimod PH20 SC, Placebo, prednisone - Pemphigus Vulgaris, Pemphigus Foliaceus | Phase 3 | Completed | argenx | 222 | 2020-12-01 | 2024-10-01 |
| A Study of PRN1008 in Patients With Pemphigus Rilzabrutinib, Placebo - Pemphigus | Phase 3 | Terminated | Principia Biopharma, a Sanofi Company | 131 | 2019-01-08 | 2023-08-02 |
| Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent) - Pemphigus | Phase 3 | Terminated | GlaxoSmithKline | 1 | 2015-12-23 | 2017-06-14 |
| A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Mycophenolate Mofetil Placebo, Mycophenolate Mofetil, Rituximab - Pemphigus Vulgaris | Phase 3 | Completed | Hoffmann-La Roche | 135 | 2015-05-26 | 2020-11-10 |
| Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus Rituximab and Cyclophosphamide IV - Pemphigus | Phase 3 | Unknown | Uprety Shraddha | 20 | 2013-11-01 | 2014-10-30 |
| Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris Ofatumumab, Placebo - Pemphigus Vulgaris | Phase 3 | Terminated | Novartis Pharmaceuticals | 35 | 2013-08-13 | 2019-06-06 |
| Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab Rituximab - Pemphigus | Phase 3 | Completed | University Hospital, Rouen | 22 | 2011-06-01 | 2012-09-13 |
| A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV) Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day, Placebo - Pemphigus Vulgaris (PV) | Phase 3 | Completed | Hoffmann-La Roche | 96 | 2004-05-01 | 2011-06-22 |
| Effect of Anti CD20 in Pemphigus Desease Mabthera - Pemphigus | Phase 2 / Phase 3 | Completed | University Hospital, Rouen | 22 | 2003-06-01 | 2013-06-18 |
| European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus dexamethasone (50mg 1dd6, 3 consecutive days/month) - Pemphigus | Phase 2 / Phase 3 | Completed | University Medical Center Groningen | 60 | 2001-01-01 | 2007-08-30 |
Autoimmune Diseases (1) · Pemphigoid, Bullous (1) · Rare Diseases (1)
Immune System Diseases (14) · Skin Diseases (14) · Skin Diseases, Vesiculobullous (14) · Skin and Connective Tissue Diseases (14) · Autoimmune Diseases (13) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Rituximab (4) · Prednisone (3) · Mycophenolic Acid (2) · ofatumumab (2) · Acetaminophen (1) · Cetirizine (1) · Dexamethasone (1) · Histamine Antagonists (1) · Prednisolone (1) · tirabrutinib (1)
Hoffmann-La Roche (2) · University Hospital, Rouen (2) · argenx (2) · Cairo University (1) · GlaxoSmithKline (1) · Novartis Pharmaceuticals (1) · Ono Pharmaceutical Co., Ltd. (1) · Principia Biopharma, a Sanofi Company (1) · Shanghai Jiaolian Drug Research and Development Co., Ltd (1) · University Medical Center Groningen (1) · Uprety Shraddha (1)
United States (7) · France (6) · Israel (6) · Australia (5) · Germany (5) · Italy (5) · Turkey (Türkiye) (5) · Ukraine (5) · Greece (4) · Japan (4) · Poland (4) · Spain (4) · United Kingdom (4) · Bulgaria (3) · Canada (3)
Marcel F Jonkman, MD, PhD (1) · Mohamed El-Shazly, MD (1) · Project Leader (1) · Shraddha Uprety, MBBS (1)
PMID 16702494, PMID 17687130, PMID 20410913, PMID 34097368
2014 (1), 2018 (1)